SCHEMBL25834703

SCHEMBL25834703

CC(C)CCOCCC(=O)NCCOCCNC(=O)CCOCCC(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
ALDH1A1 P00352 1/20 0.46
HPGD P15428 2/20 0.44
CNR1 P21554 2/20 0.41
CNR2 P34972 1/20 0.41
LMNA P02545 2/20 0.40
PKM P14618 1/20 0.40
TSHR P16473 1/20 0.39
TDP1 Q9NUW8 1/20 0.37
CA12 O43570 4/20 0.36
CA1 P00915 4/20 0.36
CA2 P00918 4/20 0.36
CA4 P22748 4/20 0.36
CA9 Q16790 4/20 0.36
CA14 Q9ULX7 4/20 0.36
HTT P42858 2/20 0.35
POLB P06746 1/20 0.35
NAMPT P43490 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17874808 1.00 MEN1 (0.47) MEN1KMT2AALDH1A1HPGDCNR1
SCHEMBL25834766 0.98 MEN1 (0.50) MEN1KMT2AALDH1A1HPGDCNR1
SCHEMBL26031870 0.98 MEN1 (0.50) MEN1KMT2AALDH1A1HPGDCNR1
SCHEMBL23334288 0.98 MEN1 (0.50) MEN1KMT2AALDH1A1HPGDCNR1
SCHEMBL18239178 0.93 MEN1 (0.42) MEN1KMT2AALDH1A1HPGDCNR1
SCHEMBL11912086 0.93 ALDH1A1 (0.50) MEN1KMT2AALDH1A1HPGDCNR1
SCHEMBL21311576 0.92 MEN1 (0.45) MEN1KMT2AALDH1A1HPGDCNR1
SCHEMBL21579903 0.92 MEN1 (0.45) MEN1KMT2AALDH1A1HPGDCNR1
SCHEMBL24919864 0.92 MEN1 (0.45) MEN1KMT2AALDH1A1HPGDCNR1
SCHEMBL18306913 0.92 MEN1 (0.45) MEN1KMT2AALDH1A1HPGDCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS CPT1B, MUSK, MYLK2 MEN1 4753/4885KMT2A 1603/4885ALDH1A1 1330/4885
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 MEN1 4828/4885KMT2A 3122/4885ALDH1A1 2528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.